European Society of Cardiology (ESC) 2022
Four new guidelines were published by the ESC: ventricular arrhythmias and sudden death, cardio-oncology, pulmonary hypertension, and the assessment of patients undergoing non-cardiac surgery
Comments and findings:
• Confirmation of the foundational role of SGLT-2 inhibitors in the treatment of heart failure across the full spectrum of ejection fraction
• Acknowledgement of the need for cardiologists to adopt GLP-1RAs as integral to the management of diabetes and cardiovascular disease
• The need for early and longer-term treatment with a combination of lipid-lowering agents to reduce coronary artery disease events was stressed by experts based on randomised controlled trials and meta-analyses.